Ondine Biomedical Share Discussion Threads

[purple11] 25/3/2024 08:04

whos to say it will be at a discount.the last one was done at a premium

[nchanning] 25/3/2024 07:57

Not sure how I can buy this when there must be a huge discounted placing coming . Great tech , would be delighted to buy once refinanced

[luzley] 25/3/2024 07:49

The ongoing gamechanger is that the last NHS related news was in oropharyngeal surgery where nasal bacteria and viruses are in the nasal region. This adoption is in orthopaedics....that is highly significant and has been trialed and proven to massively reduce post operative infection. HAI's cost the NHS a fortune and this potentially opens the door to widespread pre-op Steriwave use across all NHS ops. Huge opportunity and validated.

[jailbird] 25/3/2024 07:40

Excellent news So far this year .

[z1co] 25/3/2024 07:19

After this first deals , i expect many more and Steriwave will most definitely take off in the UK like it has Canada.

Not so good if you've sold and were deramping last week!!!

[z1co] 25/3/2024 07:14

Excellent news:

25 March 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

First commercial adoption of Steriwave by the NHS

NHS deal gives patients access to groundbreaking light-activated antimicrobial to combat AMR (antimicrobial resistance)

· A new light-activated antimicrobial that kills all types of bugs - viruses, bacteria, and fungi - in minutes without generating resistance is being adopted by two NHS hospitals to reduce surgical infections.

Mid Yorkshire Teaching NHS Trust has approved the commercial adoption of Ondine's groundbreaking light-activated antimicrobial, Steriwave®. The approval will see the use of Steriwave expanded across hip and knee surgery patients at Pontefract and Pinderfields NHS Hospitals to reduce the incidence of surgical site infections (SSIs). This adoption as standard-of-care for orthopedic patients follows a successful, initial deployment that is being used to evaluate Steriwave at Pontefract Hospital.

Dr Stuart Bond, Consultant antimicrobial pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented:

"We are very pleased to be the first NHS Trust to be giving patients access to this important new technology. SSIs can have a devastating effect on patients and their families, and we are pleased that we have demonstrated the feasibility of using Steriwave in our Orthopaedic Centre of Excellence at Pontefract Hospital. It is a real step forward to making Steriwave more widely available across the Trust."

[bamboo2] 25/3/2024 07:13

Expansion planned.

================


The full findings of this study [are expected to be reported on later this year and] will be used to support the further spread and adoption of Steriwave across the NHS and across additional surgical applications.

[bamboo2] 25/3/2024 07:11

First commercial adoption of Steriwave by the NHS

NHS deal gives patients access to groundbreaking light-activated antimicrobial to combat AMR (antimicrobial resistance)

· A new light-activated antimicrobial that kills all types of bugs - viruses, bacteria, and fungi - in minutes without generating resistance is being adopted by two NHS hospitals to reduce surgical infections.

Mid Yorkshire Teaching NHS Trust has approved the commercial adoption of Ondine's groundbreaking light-activated antimicrobial, Steriwave®. The approval will see the use of Steriwave expanded across hip and knee surgery patients at Pontefract and Pinderfields NHS Hospitals to reduce the incidence of surgical site infections (SSIs). This adoption as standard-of-care for orthopedic patients follows a successful, initial deployment that is being used to evaluate Steriwave at Pontefract Hospital.

Dr Stuart Bond, Consultant antimicrobial pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented:

"We are very pleased to be the first NHS Trust to be giving patients access to this important new technology. SSIs can have a devastating effect on patients and their families, and we are pleased that we have demonstrated the feasibility of using Steriwave in our Orthopaedic Centre of Excellence at Pontefract Hospital. It is a real step forward to making Steriwave more widely available across the Trust."

The CEO of Ondine Biomedical, a world leader in light-activated antimicrobial technology, Carolyn Cross, said:

"We are delighted to see the first two NHS hospitals adopt Steriwave, particularly as NHS is seen around the world as a leader in antibiotic stewardship in response to the growing threat of AMR (antimicrobial resistance). This is not only a significant milestone for Ondine, but Mid Yorks's accelerated decision to adopt suggests that Steriwave has been well received by patients, surgeons, and nurses."

As announced on 5 March 2024, Ondine Biomedical, Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire & Humber have partnered to sponsor a health economic analysis with the York Health Economics Consortium (YHEC). The full findings of this study [are expected to be reported on later this year and] will be used to support the further spread and adoption of Steriwave across the NHS and across additional surgical applications.

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS.[1] SSIs can cost up to £100,000 per patient,[2] and the overall cost of HAIs to NHS England is over £2 billion a year.[3] These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.[4]

Steriwave is a light-activated antimicrobial that uses a specific wavelength of red light to destroy pathogens that colonise the nose and can spread to cause harmful infections. Crucially, unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger antimicrobial resistance (AMR). Nasal decolonization - eliminating harmful pathogens from the nasal cavities - is recommended by WHO and NICE prior to surgery as a key approach to preventing SSIs.[5]

Steriwave has been used in over 150,000 patient treatments, including at major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute. Research recently published by VGH in the Canadian Journal of Surgery showed that the use of Steriwave in patients undergoing spine surgery resulted in a 66.5% reduction in post-surgical infection rates and almost $2600 per spine surgery patient, representing $2.5 million in annual savings for Vancouver General Hospital's spine group.[6] No serious adverse events have ever been reported from Steriwave treatment.

[jailbird] 22/3/2024 20:44

Luzley,

Phase 3 - non-dilutive funding opportunities and numerous AMR-related government initiatives.

but for near term funding - it will be dilution again from last RNS

[luzley] 21/3/2024 16:03

Ondine has specifically addressed any need for funding in its last interim. This was prior to the investor-led financing at 9p - a premium to the shareprice at the time. The CEO quotes:The rise of antimicrobial resistance ("AMR") is driving governments and research institutes to seek new solutions to combat antimicrobial-resistant pathogens and help prevent millions of deaths. Because of the demonstration of efficacy against ESKAPE and extremely drug-resistant pathogens of major concern to global health authorities, we are accelerating our pursuit of non-dilutive funding opportunities and numerous AMR-related government initiatives.Multiple agencies have consistently identified a select group of pathogens (i.e., the ESKAPE pathogens) responsible for the majority of HAIs. Many of the same microorganisms are notorious for their tenacity, pathogenicity, virulence, proclivity for resistance and ultimately, the severity of their infections.

[luzley] 21/3/2024 15:35

Jumped up on volume but drifted back a little on drips and draws. Expect next move north as tech is proving expansive and sticky now. Word of mouth between consultants and health trusts are becoming the new driver. Good news on reducing cost burdens is the key. I'm patient here. The horizon is so bright in this desperate-for-a-solution antibiotic war that funding if needed should be no problem at the current price. CEO has loads of skin in the game and I actually suspect that the recent CFO appointment is related to her exit strategy in the near future.

[eigthwonder] 21/3/2024 11:47

Be careful about thinking about big picture prizes when shorter term funding realities could trip it up.

[luzley] 21/3/2024 11:12

And it was done at a premium. This is being shown to save millions when employed in reducing hospital acquired infections and subsequent bed blocking. Antibiotic resistance is THE biggest threat to mankind and we are running out of solutions. Steriwave is one Huge part of the answer. I reckon Halma will take this out or similar.

[purple11] 21/3/2024 11:03

personally im in @9p with a stop loss at 8.25p so i have minimun downside risk but hope to capture profits on a success case.gl

[purple11] 21/3/2024 11:02

last year obi had revenues of $600,000 and lost $19 million
and thats after selling this product for 10 YEARS

that is why this is a very risky PUNT

it cant be decribed as anything other than that.

they are about to do another placing and we dont know the strike price or the level of dilution.

this could v well trade up to 60-100p on a success case

it could also fail to gain traction ,be diluted to death and end up at 1p like all the other AIM biomed stocks listed.

only gamble what you can afford to lose and you will remain happy.

[z1co] 21/3/2024 09:41

You're so pathetic and a LIAR.

Hey go and post on your own thread and stop trolling me.

WOW all this harassment because you lost a few bobs on PPP.

[purple11] 21/3/2024 09:36

i havent sold loser

[purple11] 21/3/2024 09:23

it doesnt reade well that this has been used for 10 years with miniscule revenues......and theres a placing happening......

certainly v risky

[jailbird] 21/3/2024 09:12

Hi Jeanesy,

Do not know yet. We just had one couple of months ago at 9p.

[jeanesy] 21/3/2024 09:04

what price the placing if there is to be one ?

[jailbird] 21/3/2024 08:53

well market seems to agree

[z1co] 21/3/2024 08:05

JB has become the troll like he was before , obviously he must have also sold his trade yesterday for a small loss.

He also started to deramp late yesterday afternoon

[jailbird] 21/3/2024 08:01

Sounds more like a non-RNS.

I think this may be sent put to boost the fund raising strike price

[z1co] 21/3/2024 07:59

Great interview.

Steriwave will also take off in the UK like it has in Canada.